<DOC>
	<DOCNO>NCT00398086</DOCNO>
	<brief_summary>To determine maximum tolerate dose dose-limiting toxicity Gemcitabine plus Albumin-bound paclitaxel ( ABI-007 ) patient advance metastatic pancreatic cancer .</brief_summary>
	<brief_title>Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer</brief_title>
	<detailed_description>Albumin-bound paclitaxel novel , solvent-free , albumin-bound , 130 nanometer particle form paclitaxel design avoid problem associated solvent use Taxol ( Abraxane prescribe information 2005 ) . Albumin number property make attractive molecule combine paclitaxel . Albumin natural transporter endogenous hydrophobic molecule water-insoluble vitamin hormone ( Vorum 1999 ) albumin bind gp-60 receptor ( albondin ) initiate caveolae-mediated endothelial transport protein-bound unbound plasma constituent ( John et al 2003 , Minshall et al 2003 , Tiruppathi et al 1997 ) . This study consist Phase 1 dose escalation phase , Phase 2 treatment phase 24-month follow-up phase .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Patient histologically cytologically confirm metastatic adenocarcinoma pancreas . Patients islet cell neoplasms exclude . Male nonpregnant nonlactating female , age great equal 18 . If female patient childbearing potential , evidence regular menstrual period , must negative serum pregnancy test betahuman chorionic gonadotropin ( BhCG ) document within 72 hour first administration study drug . If sexually active , patient must agree use contraception consider adequate appropriate investigator . Patient must receive prior therapy treatment metastatic disease . Prior treatment 5fluorouracil ( 5FU ) gemcitabine administer radiation sensitizer 4 week radiation therapy allow . If patient receive gemcitabine adjuvant setting , tumor recurrence must occur least 6 month complete last dose gemcitabine . Patient follow blood count baseline Absolute neutrophil count ( ANC ) equal great 1.5 x 10^9/L ; Platelets equal great 100 x 10^9/L Hemoglobin equal great 9 g/dL . Patient follow blood chemistry level baseline : Aspartate aminotransferase ( SGOT ) , Alanine aminotransferase ( SGPT ) equal less 2.5 x upper limit normal range ( ULN ) allow Bilirubin less equal ULN Serum creatinine within normal limit calculate clearance equal great 60 mL/min/1.73M^2 patient serum creatinine level institutional normal value Patient clinically significant abnormality urinalysis result Patient acceptable coagulation status indicate prothrombin time ( PT ) within normal limit ( plus minus 15 % ) partial thromboplastin time ( PTT ) within normal limit ( plus minus 15 % ) . Patient Karnofsky performance status ( KPS ) great equal 70 ( Eastern Cooperative Oncology Group [ ECOG ] PS 01 ) . Patient one metastatic tumor measurable compute tomography ( CT ) scan . Patient inform nature study , agree participate study , sign Informed Consent form prior participation studyrelated activity . Patient known brain metastasis unless previously treat well control least 3 month ( define stable clinically , edema , steroid stable two scan least 4 week apart ) . Patient use therapeutic coumadin history pulmonary embolus deep vein thrombosis ( DVT ) . Patient active , uncontrolled bacterial , viral , fungal infection ( ) require systemic therapy . Patient known infection human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C. Patient undergone major surgery , diagnostic surgery i.e . do obtain biopsy diagnosis without removal organ ) , 4 week prior Day 1 treatment study . Patient receive radiotherapy , surgery , chemotherapy , investigational therapy within 3 week prior study entry week ( 6 week nitrosureas mitomycin C ) . Patient history allergy hypersensitivity study drug . Patient serious medical risk factor involve major organ system investigator considers unsafe patient receive experimental research drug . Patient unwilling unable comply study procedure . Patient enrol clinical protocol investigational trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Metastatic Pancreatic Cancer , Abraxane , Gemcitabine</keyword>
</DOC>